Cardiovascular Benefits of Menopause Hormone Treatment is Age-Dependent in Ldlr-/- Mice
This study demonstrates that the cardiovascular benefits of estrogen therapy in atherosclerotic mice are age-dependent, as aging triggers hepatic estrogen receptor remodeling that promotes inflammation and oxidative stress, thereby negating the treatment's protective effects in older mice while remaining beneficial in younger ones.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
For decades, a medical mystery has puzzled doctors and patients alike. Women are generally protected from heart disease until they reach menopause, a time when their bodies stop producing estrogen, a hormone that helps keep blood vessels healthy. Once that protection fades, the risk of clogged arteries and heart attacks rises sharply. It seemed logical that giving women back that missing hormone through therapy would restore their heart health. Yet, large clinical trials have shown a frustrating reality: while hormone therapy improves blood sugar and cholesterol numbers, it does not consistently prevent heart attacks or strokes, especially in older women or those who already have heart disease. The question has lingered: why does the treatment fix the numbers but fail to fix the heart?
To find the answer, researchers turned to a living model of the human condition. They used mice that were genetically prone to developing clogged arteries, similar to humans with high cholesterol. They created a scenario that mimics the human experience of aging and menopause. First, they fed the mice a diet rich in fat to build up significant plaque in their arteries, simulating established heart disease. Then, they switched the mice to a healthy, low-fat diet to lower their cholesterol levels, just as a doctor might prescribe for a patient. Finally, they performed surgery to remove the mice's ovaries, inducing menopause, and treated some of them with estrogen while leaving others untreated. By comparing young mice with older mice, the scientists could see how the body's response to the hormone changed over time.
The results revealed a stark difference between the young and the old. In the younger mice, giving estrogen after menopause worked as hoped. It reduced the inflammation inside the artery walls, improved the function of the good cholesterol that cleans out plaque, and actually helped shrink the existing heart disease. However, in the older mice, the same treatment produced a different, and dangerous, outcome. Even though their blood lipid levels improved, the estrogen treatment failed to reduce the plaque. Instead, it triggered a surge in a specific inflammatory signal within the body. This signal made the "good" cholesterol lose its ability to protect the arteries and even turned it into a substance that could not fight off the damage caused by oxidation. The arteries in the older mice remained clogged and vulnerable, despite the treatment.
The scientists then investigated why this switch happened. They discovered that as the mice aged, the way their liver cells received and processed the estrogen signal changed. In the young mice, the hormone signaled the liver to burn fat for energy in a clean, efficient way. In the older mice, the liver cells had changed their receptors, the tiny antennas that catch the hormone's message. They became less sensitive to the protective signals and more responsive to signals that caused stress and inflammation. This shift led to a buildup of toxic byproducts in the liver, which in turn fueled a persistent state of inflammation throughout the body. This inflammation acted like a brake, stopping the estrogen from doing its job of clearing out the heart disease.
To prove that inflammation was the true culprit, the researchers performed a delicate experiment. They took older mice that had received the estrogen treatment and replaced their blood-forming cells with cells from mice that could not produce that specific inflammatory signal. When the inflammation was blocked, the estrogen treatment suddenly worked again. The older mice saw their plaque shrink, their arteries become less vulnerable, and their good cholesterol regain its protective power. This confirmed that the hormone itself was not broken; rather, the aging body had created an environment of inflammation that neutralized the hormone's benefits.
The study suggests that the failure of hormone therapy in older women is not because the treatment stops working, but because the aging body reacts to it differently. The liver, which plays a central role in metabolism, undergoes a remodeling process as we age. It shifts from a state of clean energy burning to one of stress and inflammation. When estrogen is introduced in this environment, it inadvertently fuels the fire rather than putting it out. The research indicates that for hormone therapy to be truly effective for heart health in older women, it may need to be paired with strategies that calm this specific type of inflammation. Without addressing the inflammatory backdrop, the hormone may improve blood numbers but leave the heart disease untouched, explaining why the treatment has been inconsistent in clinical trials for decades.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.